Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

$24.99

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Short-term Activity Ratios (Summary)

Amgen Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analysis of short-term operating activity ratios reveals a period of significant volatility peaking in late 2023, followed by a sustained improvement in operational efficiency and cash flow velocity through early 2026. While receivable collection periods have lengthened, these offsets are outweighed by substantial gains in inventory turnover and a reduction in the overall cash conversion cycle.

Inventory Management Efficiency
Inventory turnover exhibited a notable decline reaching a trough of 0.89 in December 2023, which corresponded with a peak in the average inventory processing period of 411 days. However, a strong recovery trend followed, with turnover increasing to 1.91 by March 2026. This improvement is reflected in the average inventory processing period, which decreased from its peak to 191 days, indicating a more streamlined movement of goods.
Receivables and Collections
A gradual downward trend is observed in the receivables turnover, declining from 4.81 in March 2022 to 3.88 in March 2026. Consequently, the average receivable collection period expanded from 76 days to 94 days over the analyzed period. This indicates a slower rate of converting credit sales into cash, suggesting a potential shift in credit terms or a slowdown in customer payment behavior.
Payables and Liquidity Management
Payables turnover remained volatile, with values fluctuating between a high of 6.74 in December 2024 and a low of 4.02 in March 2026. The average payables payment period showed no linear trend, varying between 54 and 91 days. The increase in the payment period toward the end of the period suggests a strategic extension of payment terms to suppliers to preserve liquidity.
Working Capital and Operating Cycles
Working capital turnover experienced extreme variance, dropping to levels near 0.81 in 2023 before surging to a peak of 9.85 in December 2024. The operating cycle mirrored the inventory trends, peaking at 510 days in December 2023 before contracting to 285 days by March 2026. This contraction signifies a more efficient transition from raw materials to cash collection.
Cash Conversion Cycle (CCC)
The cash conversion cycle provides the most comprehensive view of operating efficiency. After a significant expansion to 441 days in December 2023, the CCC entered a steady decline, reaching 194 days by March 2026. This indicates that the acceleration in inventory turnover and the extension of payables payment periods more than compensated for the slowing receivables collection, resulting in a more efficient cash regeneration process.

Turnover Ratios


Average No. Days


Inventory Turnover

Amgen Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of sales
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Inventory turnover = (Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025 + Cost of salesQ2 2025) ÷ Inventories
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of operating activity reveals a period of significant volatility in late 2023, followed by a sustained trend of improved inventory efficiency through the first quarter of 2026. The operational cycle transitioned from a stable phase to a period of high inventory accumulation and subsequently to a lean management phase characterized by higher turnover rates.

Cost of Sales Trends
Expenditures remained relatively consistent between March 2022 and September 2023, generally fluctuating between 1,510 million and 1,813 million US$. A substantial increase occurred on December 31, 2023, where costs rose to 3,112 million US$. This elevated baseline persisted through 2024 and 2025, peaking at 3,310 million US$ in September 2024, before slightly moderating to 2,744 million US$ by March 31, 2026.
Inventory Level Fluctuations
Inventory assets grew steadily from 4,411 million US$ in March 2022 to 5,026 million US$ in September 2023. A sharp spike was recorded on December 31, 2023, reaching a peak of 9,518 million US$. Following this peak, a consistent and systematic reduction in inventory levels was observed, with values declining quarterly to 6,186 million US$ by March 31, 2026.
Inventory Turnover Performance
The inventory turnover ratio exhibited stability between 1.30 and 1.48 during the first eighteen months of the period. A significant contraction occurred on December 31, 2023, with the ratio dropping to its lowest point of 0.89, coinciding with the peak in inventory holdings. However, a strong recovery trend followed, with the ratio climbing steadily from 1.14 in March 2024 to a peak of 1.93 in December 2025, eventually stabilizing at 1.91 by March 31, 2026.

The data suggests that the sharp increase in inventory and the corresponding dip in turnover in late 2023 represented a temporary anomaly. The subsequent period demonstrates a successful optimization of the supply chain or a strategic drawdown of stock, resulting in a significantly more efficient inventory-to-sales conversion rate compared to the initial 2022-2023 baseline.


Receivables Turnover

Amgen Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Product sales
Trade receivables, net
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Receivables turnover = (Product salesQ1 2026 + Product salesQ4 2025 + Product salesQ3 2025 + Product salesQ2 2025) ÷ Trade receivables, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity indicates a general decline in the efficiency of receivables collection over the observed period. While product sales have demonstrated substantial growth, the corresponding increase in net trade receivables has occurred at a rate that frequently offset revenue gains, resulting in a downward trajectory for the receivables turnover ratio.

Product Sales Performance
Product sales exhibited a consistent upward trend, rising from 5,731 million USD in March 2022 to a peak of 9,367 million USD in December 2025. This growth suggests a significant expansion in market reach or pricing power, although a contraction to 8,218 million USD was noted by March 2026.
Trade Receivables Growth
Net trade receivables increased from 5,077 million USD in March 2022 to 9,138 million USD in March 2026. A notable peak occurred in December 2025 at 9,570 million USD. The growth in receivables closely mirrors the growth in sales, but the periodic surges in receivable balances have negatively impacted the turnover efficiency.
Receivables Turnover Ratio Trends
The receivables turnover ratio declined from a high of 4.81 in March 2022 to 3.88 in March 2026. A period of steady erosion was observed through December 2023, where the ratio reached 3.70. A temporary recovery occurred during 2024, peaking at 4.72 in December 2024, indicating a brief improvement in collection velocity.
Collection Efficiency and Volatility
The ratio experienced further volatility in 2025, dropping to a period low of 3.67 in December 2025. The overall trend suggests that the company is taking longer to convert its credit sales into cash, as the ratio has not returned to the levels seen in early 2022. The discrepancy between the peak sales in December 2025 and the simultaneous low in turnover suggests a buildup of outstanding invoices during the high-growth phase.

Payables Turnover

Amgen Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of sales
Accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Payables turnover = (Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025 + Cost of salesQ2 2025) ÷ Accounts payable
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


An analysis of operating activity reveals a significant expansion in the scale of expenditures and a corresponding shift in the management of trade obligations between March 2022 and March 2026. A notable structural shift occurred in the fourth quarter of 2023, where operating costs increased substantially and remained at an elevated plateau through early 2026.

Cost of Sales Trends
Operating costs remained relatively stable between 1.5 billion and 1.8 billion US dollars throughout 2022 and the first three quarters of 2023. However, a sharp increase is observed in December 2023, with costs rising to 3.1 billion US dollars. This elevated expenditure level persisted throughout 2024 and 2025, generally fluctuating between 2.9 billion and 3.3 billion US dollars, before a slight contraction to 2.7 billion US dollars by March 2026.
Accounts Payable Dynamics
Obligations to suppliers followed a gradual upward trajectory, beginning at 1.4 billion US dollars in March 2022. A marked increase in leverage is evident starting in mid-2024, with payables climbing from 1.6 billion US dollars in March 2024 to a peak of 3.0 billion US dollars by June 2025. Despite a temporary dip in the latter half of 2025, the balance remained high, ending at 2.9 billion US dollars in March 2026.
Payables Turnover Performance
The payables turnover ratio exhibited significant volatility, reflecting changing efficiencies in liability management. The ratio initially fluctuated between 4.08 and 5.67 from 2022 to 2023. A period of increased turnover efficiency was observed in 2024, peaking at 6.74 in December 2024, which suggests a more rapid settlement of obligations relative to the cost of sales. However, a downward trend emerged in 2025 and early 2026, with the ratio falling to 4.02 by March 2026. This decline indicates a lengthening of the payment cycle and a greater reliance on supplier financing to support the increased cost of sales.

The overall correlation between the doubling of the cost of sales and the eventual doubling of accounts payable suggests an operational scaling. The recent decline in the turnover ratio indicates that the organization is currently extending its payment terms or managing a larger volume of outstanding trade credit compared to the peak efficiency seen in 2024.


Working Capital Turnover

Amgen Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Product sales
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Working capital turnover = (Product salesQ1 2026 + Product salesQ4 2025 + Product salesQ3 2025 + Product salesQ2 2025) ÷ Working capital
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals significant volatility in working capital management and a corresponding impact on the efficiency of asset utilization between March 2022 and March 2026. While product sales exhibited a general upward trajectory, the working capital turnover ratio experienced extreme fluctuations, driven primarily by a substantial surge in working capital during the first three quarters of 2023.

Working Capital Dynamics
Working capital remained relatively stable throughout 2022, ranging between 5.6 billion and 9.7 billion US$. However, a sharp increase occurred in early 2023, peaking at 31.5 billion US$ by September 30, 2023. This period of expansion was followed by a rapid contraction starting in December 2023, with levels normalizing between 3.5 billion and 8.3 billion US$ from 2024 through March 2026.
Product Sales Growth
A consistent growth pattern in product sales is observed over the analyzed period. Sales increased from an average of approximately 6 billion US$ per quarter in 2022 to peaks exceeding 9 billion US$ in late 2025. This steady rise in revenue provided a stable numerator for the turnover ratio, indicating that the fluctuations in efficiency were driven by balance sheet changes rather than revenue instability.
Working Capital Turnover Efficiency
The turnover ratio demonstrates an inverse relationship with the working capital spikes. The ratio declined from 4.34 in March 2022 to a low of 0.81 in September 2023, reflecting a temporary period of decreased operational efficiency or a strategic accumulation of current assets. Following the reduction in working capital in late 2023, the ratio recovered sharply, reaching a peak of 9.85 in December 2025. This suggests a significantly more lean approach to managing short-term assets in the latter half of the period.
Comparative Performance Trends
The operational efficiency in 2024 and 2025 represents a marked improvement over 2022 and 2023 levels. The turnover ratios in the final two years of the data generally remained above 5.0, compared to the sub-4.0 levels seen in the initial period. This shift indicates that the organization is generating substantially more revenue per dollar of working capital employed than it did at the start of the analysis period.

Average Inventory Processing Period

Amgen Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of inventory efficiency from March 2022 through March 2026 reveals a period of initial volatility followed by a sustained improvement in operational velocity.

Inventory Turnover Ratio
The turnover ratio exhibited a gradual decline from 1.48 in March 2022 to 1.30 by December 2022. After a marginal recovery throughout most of 2023, a significant contraction occurred on December 31, 2023, where the ratio fell to a period low of 0.89. From early 2024 onward, a consistent upward trend was established, with the ratio increasing to a peak of 1.93 by December 2025 and concluding the period at 1.91 in March 2026.
Average Inventory Processing Period
The time required to process inventory moved in inverse correlation with the turnover ratio. The processing period extended from 247 days in March 2022 to 281 days by December 2022. A notable spike is observed in December 2023, where the period reached a maximum of 411 days. This peak was followed by a steady and significant reduction, with the processing period falling below 200 days by December 2024 and stabilizing between 189 and 191 days throughout 2025 and early 2026.

The data highlights a critical operational anomaly in the fourth quarter of 2023, characterized by a sharp increase in the processing period and a corresponding drop in turnover. However, the subsequent trend indicates a substantial optimization of inventory management. By the end of the observed period, the efficiency levels surpassed the initial 2022 baselines, reflecting a more streamlined conversion of inventory into sales.


Average Receivable Collection Period

Amgen Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An overall increase in the average receivable collection period is observed between March 2022 and March 2026, indicating a general deceleration in the conversion of accounts receivable into cash. While there were periods of recovery, the duration required to collect payments has trended upward from an initial 76 days to 94 days over the analyzed timeframe.

Average Receivable Collection Period Trends
The collection period exhibited a steady increase from 76 days in March 2022 to 88 days by September 2023, culminating in a peak of 99 days in December 2023. A notable improvement occurred throughout 2024, where the collection period declined to a low of 77 days by December 2024. However, this efficiency was temporary, as the period rose again to 95 days by June 2025 and peaked again at 99 days in December 2025, before settling at 94 days in March 2026.
Receivables Turnover Correlation
The receivables turnover ratio demonstrates a consistent inverse relationship with the collection period. Higher turnover ratios, such as 4.81 in March 2022 and 4.72 in December 2024, coincide with the shortest collection windows. Conversely, the lowest turnover ratios, recorded at 3.70 in December 2023 and 3.67 in December 2025, align precisely with the peaks in the collection period, reflecting decreased efficiency in asset utilization during those intervals.
Seasonal and Cyclical Patterns
A recurring cyclical pattern is evident, characterized by spikes in the collection period during the fourth quarter of the year. The synchronized peaks of 99 days in December 2023 and December 2025 suggest a systemic seasonal influence, potentially linked to year-end billing cycles, customer payment behavior, or adjustments in credit terms at the close of the calendar year.

Operating Cycle

Amgen Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


The operating cycle demonstrates a period of significant volatility between 2022 and 2024, followed by a phase of stabilization and improved efficiency through the first quarter of 2026. The overall trend is characterized by a substantial expansion in the duration of the cycle that peaked in late 2023, primarily driven by fluctuations in inventory management.

Average Inventory Processing Period
A general upward trend was observed from March 2022, when the period stood at 247 days, culminating in a sharp peak of 411 days in December 2023. Subsequent to this peak, there was a consistent and significant contraction in processing time, falling to 189 days by December 2025. This trajectory indicates a period of inventory accumulation or inefficiency followed by a successful optimization of inventory turnover.
Average Receivable Collection Period
The collection period exhibited more stability than the inventory period, though a gradual increase is evident. The period rose from 76 days in March 2022 to a high of 99 days in December 2023 and again in December 2025. The fluctuations between 77 and 99 days suggest a moderate lengthening of the time required to convert receivables into cash over the analyzed timeframe.
Operating Cycle
The total operating cycle mirrored the volatility of the inventory processing period, starting at 323 days in March 2022 and reaching a maximum of 510 days in December 2023. A corrective downward trend followed, with the cycle stabilizing between 280 and 295 days from June 2024 through March 2026. The reduction in the overall cycle length indicates an improvement in the speed of the working capital loop, reducing the duration between the initial outlay for inventory and the final collection of cash from sales.

Average Payables Payment Period

Amgen Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity indicates significant volatility in the management of accounts payable over the observed period from March 2022 through March 2026. The data reveals a cyclical pattern in the timing of supplier payments, characterized by a prolonged period of acceleration followed by a sharp deceleration in payment velocity.

Average Payables Payment Period Trends
A general downward trajectory in the payment period was observed from March 2022 (78 days) through December 2024, where the period reached its minimum of 54 days. This compression suggests a phase of more rapid settlement of obligations to vendors. However, this trend reversed sharply starting in March 2025, with the payment period extending to 89 days by June 2025 and ultimately peaking at 91 days by March 2026.
Payables Turnover Correlation
The payables turnover ratio exhibits a strong inverse correlation with the payment period. The highest turnover efficiency was recorded in December 2024 at 6.74, coinciding with the shortest payment window of 54 days. Conversely, the lowest turnover ratios were observed in December 2022 (4.08) and March 2026 (4.02), mirroring the peaks in the payment period of 90 and 91 days, respectively.
Operational Cycle Insights
The fluctuations indicate a shift in working capital strategy. The reduction in the payment period between 2023 and late 2024 reflects a shorter cash conversion cycle regarding liabilities. The subsequent expansion of the payment period throughout 2025 and early 2026 indicates an increase in the retention of cash, effectively utilizing trade credit as a source of short-term financing to extend the duration of available liquidity.

Cash Conversion Cycle

Amgen Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


The operational activity analysis indicates a significant volatility in the cash conversion cycle, characterized by a major peak in late 2023 followed by a sustained improvement in efficiency through early 2026. The overall trend demonstrates a contraction of the cycle from a high of 441 days to 194 days, primarily driven by optimizations in inventory management.

Average Inventory Processing Period
A period of increasing inventory holding times was observed from March 2022 to December 2023, culminating in a peak of 411 days. This represents a substantial slowdown in inventory turnover. However, a sharp reversal occurred starting in March 2024, with the period declining consistently to 191 days by March 2026. This downward trend suggests a significant enhancement in supply chain efficiency and a reduction in excess stock levels.
Average Receivable Collection Period
The collection period exhibited relative stability compared to inventory metrics, though a gradual upward trend is observable. Starting at 76 days in March 2022, the period fluctuated before reaching 94 days by March 2026. While the increase is moderate, it indicates a slight expansion in the time required to convert accounts receivable into cash.
Average Payables Payment Period
Payment terms fluctuated considerably throughout the analyzed period. A notable decline occurred between September 2023 and December 2024, reaching a low of 54 days. Subsequently, a trend toward longer payment terms emerged, with the period increasing to 91 days by March 2026. This volatility reflects shifts in supplier credit terms or strategic changes in the timing of cash outflows.
Cash Conversion Cycle (CCC)
The CCC followed the trajectory of the inventory processing period closely. After reaching a peak of 441 days in December 2023, the cycle contracted significantly. By March 2026, the CCC reached 194 days, marking a substantial improvement in the company's ability to recover its investment in working capital. The reduction in the CCC indicates a more streamlined operational flow and improved short-term liquidity.